Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 1

Status

Recruiting 4Completed 3Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Conditions

Myasthenia Gravis 4

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Interventional × efgartigimod alfa × Clear all
NCT07217587 2026-06-05

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting
115 enrolled

Myasthenia Gravis

NCT07072988 2025-09-24

OPTIMAGE

Centre Hospitalier Universitaire de Nice

Phase 4 Recruiting
50 enrolled

Myasthenia Gravis

NCT06765161 2025-07-29

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Clinique Neuro-Outaouais

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

NCT06587867 2024-09-19

Seronegative Myasthenia Gravis - Efgartigimod IV

University Health Network, Toronto

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡